Panobinostat Maintenance After HSCT fo High-risk AML and MDS

NCT04326764 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

52

Enrollment

OTHER

Sponsor class

Stopped Change of marketing authorisation holder

Conditions

Acute Myeloid Leukaemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions

DRUG: Panobinostat

Sponsor

Goethe University

Collaborators

[object Object]
[object Object]
[object Object]